Management Team, Advisers and Board Directors
Chairman and Chief Executive Officer
Agamemnon Epenetos brings more than 30 years of experience as a biopharmaceutical industry executive. He founded as chairman, Antisoma plc and Lipoxen plc listed on the London Stock Exchange and Somanta Inc. in California, USA listed on OTCBB and then acquired by Access Pharmaceuticals Inc. Agamemnon also co-founded Alexis Biotech, Lifeline and Zeincro, all private Biotech companies. During his presence in the Company, Antisoma was listed on the London Stock Exchange (LSE) at 30p per share and rose to £3.0 per share. Somanta Inc. was listed on OTCBB, at a valuation of $10m and within 12 months was acquired by Access Pharmaceuticals Inc. at $15m valuation.
Chief Scientific Officer
Christina Kousparou has over 15 years of experience in cancer research with particular expertise in protein engineering and a strong background in genetics tumor angiogenesis and hypoxia, key components in cancer stem cell research.
Declan Doogan was Senior Vice-President and Head of Worldwide Development at Pfizer Global Research & Development and more recently the CEO and Head of Research & Development at Amarin Corporation. He contributed substantially to the success of the Company's Phase III pivotal trial adding significant value to the Company.
Spyros Stylianou has considerable expertise in cancer stem cells and the Notch pathway, in particular. He created and tested the Company's lead product, TR4
Gary Bower has considerable expertise in R&D and clinical development. He previously worked at Amersham International (now GE Healthcare) and then Antisoma plc where he was the Project Leader for a global phase-III program as well as other programs.
The following leading international scientists and clinicians have agreed to join the Scientific Advisory Board of the Company:
- Sir Walter Bodmer, University of Oxford, UK. Walter has more than 30 years experience in cancer research and genetics. He was a pioneer and president of the Human Genome Project. Walter was knighted for his contributions to science, is an FRS and a member of the American Philosophical Society, the National Academy of Sciences and the America Academy of Arts and Sciences.
- Kerry Chester, University College London, UK. Kerry leads the Recombinant Antibody Therapeutics Group at the UCL Cancer Institute. Her interests are in the creation of protein-based therapeutics and their interaction with cancer targets.
- Jeff Cole, University of Birmingham, UK. Jeff is a microbial physiologist with his major focus been on how E. coli can be adapted to make useful quantities of difficult recombinant proteins.
- Adrian Harris, University of Oxford, UK. Adrian is Professor of Medical Oncology and Director of the Cancer Research UK Molecular Oncology Labs at the Weatherall Institute of Molecular Medicine. His interests are in hypoxia and angiogenesis. He is currently running over 20 Phase I and II trials of angiogenesis, HDAC and signal transduction inhibitors.
- Raymond Moellering, Scripps Research Institute, USA. Raymond is investigating cancer cell communication. Understanding the process will provide insights into many aspects of tumour progression and may identify new opportunities for therapeutic intervention.
- Mahendra Deonarain, Imperial College London, UK. Mahendra has experience in recombinant proteins and cancer drug development as well as expertise in preclinical models.